Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. - Wikidata - awgldk - TriplyDB

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

http://www.wikidata.org/entity/Q37600339

about

Oral budesonide for induction of remission in ulcerative colitis Elderly patients and inflammatory bowel disease Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis Classical and recent advances in the treatment of inflammatory bowel diseases Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases Next-Generation Therapeutics for IBD Current approaches to the management of new-onset ulcerative colitis.Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.Ulcerative Colitis: Update on Medical Management.Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis New pharmaceuticals in inflammatory bowel disease Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.Second Korean guidelines for the management of ulcerative colitis.Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.Review article: strategies for the management of chronic unremitting ulcerative colitis.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Glucocorticoid therapy for gastrointestinal diseases.Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?Ulcerative colitis: current pharmacotherapy and future directions.Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation.Treatment of IBD: where we are and where we are going.Conventional drug therapy for inflammatory bowel disease.Inflammatory bowel disease and the elderly: a review.Positioning Therapy for Ulcerative Colitis.Review article: the histological assessment of disease activity in ulcerative colitis.New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?Optimizing pharmacologic management of inflammatory bowel disease.The safety of non-biological treatments in Ulcerative Colitis.Budesonide for the treatment of ulcerative colitis.Hypoxia-dependent regulation of inflammatory pathways in immune cells Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms.Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications.

P2860

Q24186368-864D7A49-2E1F-4B4B-880E-3F498607725A Q26768270-BF0963CE-EAD7-47F7-96F8-70C985085549 Q26779042-C3477D43-3D9F-4C60-A9F5-61D09159CAFA Q26861725-D5D638A5-B244-4E35-8BAC-5EA0466AC2B7 Q26866110-5FD164BA-303C-49F0-83F2-09E5816BABF2 Q27008246-03909249-A9B6-492C-BF10-CFA0C5B77288 Q28082306-28AC2106-0B50-40B9-8200-CDA18D9E4EB2 Q33633288-18ABAC10-8AE4-4082-B88F-FDF3BCE94284 Q33819473-35A004D7-A44C-451F-A0E6-3962AE72A3FA Q34474024-FABA0F80-6DF3-4253-8011-254362C7EE43 Q35781294-B0C4E7D7-F793-40E1-82BD-61E21CAD8A90 Q35871764-9DA82302-4243-41C7-BD78-8B556C3CCE18 Q35889006-006BEA6A-4460-4917-B7CB-0FC1AB88F2DA Q35892481-94CD5717-787E-4F05-BECC-F3B1DC5C6974 Q36172156-D4C6974F-8D3A-4448-80A0-ABD3C69768B0 Q36210189-5E9CB3A1-F779-4F68-917A-1BEAB12DB25D Q36243912-2B5DC0EC-CAFF-45FD-831C-C656DB4B1E69 Q36531674-AC9F29FA-3D69-4FE3-BDA9-302E3335D2BA Q36919671-1BB6C787-92A5-44A1-AA1B-0670910772DC Q37308977-812FC0A2-1F81-43E0-B8AA-B76E6B0F65FF Q37662503-199310B5-AACB-4FE2-9B6C-7205C7506E0A Q37697523-26D67943-E6DC-46CD-A5D2-96BD77BC70DF Q38110317-5D82C783-1985-4E57-9F1C-A193552AE8BD Q38196945-5EEE0773-19FF-40C1-9B59-5294499CAA5B Q38205264-99ADED0B-F30C-46B6-B4C2-D9526A981BC3 Q38216510-6FCEC52B-5D65-4864-A60E-92A2BF5CDE25 Q38217653-302ECED9-3FAB-4340-B1E7-D9B962613F96 Q38246990-0DB53745-4F80-48B2-87A3-BBFC1CD2223E Q38285619-788582F9-5DA2-4EFE-9021-DE4AECAAA9F4 Q38293796-6BB25127-F3EE-4275-92A7-2B1079B80039 Q38419578-69DB8691-B2BB-4E2A-B229-30A87E134952 Q38542903-293D32E9-DA1D-452E-A445-F70C5CB859D7 Q38573248-852D278F-F51C-480B-AC57-F1C520E1E777 Q38625992-79FC3575-55E3-4C98-BE34-F6A535184873 Q38687407-D7956752-80EE-43DF-9C93-81FA5B4805AC Q38728164-A56E230E-D4D9-4BDC-8D51-FD757C1F7242 Q38828972-5ED93C80-CF41-4574-BBA6-DCC5255DF011 Q38907502-D24FAF89-C7A9-41B2-86EA-AA7E16B91672 Q38922030-42DEEAAC-A7EC-4019-9431-493AA6044EBE Q38950036-51796FB5-EE52-4180-8521-A70E7B996032

P2860

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

http://www.wikidata.org/entity/Q37600339

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@en

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@nl

type

label

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@en

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@nl

prefLabel

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@en

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@nl

P1433

Q37600339-0508A24A-87F0-4538-97B3-8F5A9B1D27A6

P1476

Q37600339-001B4E5B-47CE-409E-AE92-763A00B70F05

P2093

Q37600339-03EFC7F8-F6D3-4133-A6FF-F90B30CF8D56

Q37600339-0C498BD4-9227-4700-855D-1C59EBDDC68F

Q37600339-9DA283A2-407B-459D-AB57-E02C2E41E671

Q37600339-A4A35CF9-BD0A-4F19-ADB0-A0ACCC373B0B

Q37600339-AC2FDE78-AED8-4034-9A04-42B14D794EBF

Q37600339-B15F0814-981B-4524-AC70-9B0E03700A64

Q37600339-B17D82E2-0796-417B-A97D-1ED384C23C70

Q37600339-C0DAFDB0-1461-4143-BF05-B871B4B93644

Q37600339-CC5CCDE1-F8A0-42C3-8370-F077BA550991

Q37600339-E05C7F1E-384E-4226-B03B-D218CA006735

P2860

Q37600339-0291AC05-056C-4FFE-838B-57FB6AA0C297

Q37600339-084D4464-1231-449A-B6C7-31B268F44504

Q37600339-1B2613BE-BC3E-495D-AE38-46438F266C73

Q37600339-255FBFC8-8D38-4B2D-B2D7-5D941671E2AE

Q37600339-3A9C3F6D-BBC6-4E80-A0D4-3C52F1F99495

Q37600339-3EBA425E-56ED-437E-B8BA-4F678F4BEEF7

Q37600339-4155F549-CD99-43CC-BCF2-646024AE39C9

Q37600339-45701802-98A3-4268-A9E4-32B23EE4AC61

Q37600339-49DE8FC7-AF84-407A-B7DF-B37C4B57CB67

Q37600339-4A50FEC8-4BE8-40E5-AB14-E0EF3C85558E

P304

Q37600339-838F1FF0-80BA-4208-89FA-90D7A3E26F44

P31

Q37600339-84D2C2F7-9525-4F73-B5F7-32343C9ECCEA

P356

Q37600339-31FFE8E0-C553-4A86-8F76-080F58E5B2B9

P407

Q37600339-1596BFAA-1FE2-4FF9-A935-90DB5D98241F

P433

Q37600339-E1AE6E62-1AEE-497A-83A1-275E3AA17222

P478

Q37600339-BE490D5D-CEE3-4F92-953B-39424E597ED3

P50

Q37600339-6ABBA753-0DDF-43E0-AB77-3AE4D5D37BDD

P577

Q37600339-AD644419-93E3-4BAB-8B2F-61DB2EFCBBA5

P5875

Q37600339-61EAD554-2FF1-4270-BA13-F18AFCFF1500

P698

Q37600339-F46C834E-2451-437A-A820-03C27206E02D

P932

Q37600339-84AC5320-1B16-4234-86FB-64B8F3C10934

P356

GUTJNL-2012-304258

P1433

P1476

Once-daily budesonide MMX in a ...... the randomised CORE II study.

@en

P2093

E David Ballard

http://www.w3.org/2001/XMLSchema#string

Geert D'Haens

http://www.w3.org/2001/XMLSchema#string

Johan Masure

http://www.w3.org/2001/XMLSchema#string

Limas Kupcinskas

http://www.w3.org/2001/XMLSchema#string

Luigi Moro

http://www.w3.org/2001/XMLSchema#string

Matteo Rossini

http://www.w3.org/2001/XMLSchema#string

Olga Alexeeva

http://www.w3.org/2001/XMLSchema#string

Peter R Gibson

http://www.w3.org/2001/XMLSchema#string

Richard Jones

http://www.w3.org/2001/XMLSchema#string

Silvio Danese

http://www.w3.org/2001/XMLSchema#string

P2860

Oral budesonide for induction of remission in ulcerative colitis

Budesonide for induction of remission in Crohn's disease

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

Review article: defining remission in ulcerative colitis

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.

Treatment of inflammatory bowel disease: a review of medical therapy.

P304

433-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2012-304258

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

P577

2013-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235717733

http://www.w3.org/2001/XMLSchema#string

P698

23436336

http://www.w3.org/2001/XMLSchema#string

P932

3933176

http://www.w3.org/2001/XMLSchema#string